King Pharmaceutals' Q2 Beats, But Goldman Sachs Sees No Long-Term Momentum

King Pharmaceuticals

reported Q2 EPS and revenue ahead of the Street. EPS came in at $0.07 on revenues of $371 million. Goldman Sachs analysts see little upside to King despite the beat. They said, "King reported 2Q2010 EPS and revenue ahead of consensus, a welcome relief after disappointments in the preceding two quarters and consistent with our view that consensus expectations for 2010 are achievable. On the other hand, the quarter also reinforced our long-term term concerns with weakness in the pharma business highlighting risk to long-term estimates." Goldman Sachs gives King a Neutral rating with a price target of $9.50. Shares are currently trading at $9.18. You Can't Afford Miss To Out On These Money Making Trading

.